Lantern Pharma, Inc. (LTRN)
Stock Price:
$13.13 USD
0.18 (1.39%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
81.64M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
6.22M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$13.13 |
| Previous Close |
$12.95 |
| Change ($) |
0.18 |
| Change (%) |
1.39% |
| Day's Open |
13.01 |
| Day's Range |
12.97 - 13.30 |
| Day's Volume |
9,539 |
| 52-Week Range |
11.51 - 15.44 |
More Stats
| Market Cap |
81.64M |
| Enterprise Value |
81.06M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
6.22M |
| Float |
1.52M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
26,912 |
| Short Ratio |
0.05 |
| Short % of Float |
1.17% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
133.78 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
580,982 |
| Net Cash / Share |
0.09 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -2.43 | -1.73 |
| Net Income | -2.43 | -1.73 |
| Shares Outstanding | 1.14 | 1.11 |
| Earnings Per Share | -2.14 | -1.56 |
| Cash & Equivalents | 1.23 | 0.45 |
| Net Cash / Debt | 1.23 | 0.45 |
| Assets | 1.43 | 0.45 |
| Liabilities | 0.49 | 0.65 |
| Book Value | 0.94 | -0.20 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Lantern Pharma, Inc. |
| Country |
United States |
| Employees |
4 |
| CEO |
Panna L. Sharma |
Stock Information
| Ticker Symbol |
LTRN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LTRN |
| IPO Date |
June 11, 2020 |
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on leveraging artificial intelligence (A.I.), machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, a non-hormone, non-chemotherapy, next generation alkylating agent with nanomolar potency that damages DNA in cancer cells that overexpress certain biomarkers indicated primarily in solid tumors, such as those in prostate and ovarian cancers. The company was incorporated in 2013 and is based in Dallas, Texas.